265654-77-1

Basic information

• Product Name: 4-(2-Pyrrolidin-1-ylethoxy)nitrobenzene
• Synonyms: 1-[2-(4-Nitrophenoxy)ethyl]pyrrolidine;4-(2-Pyrrolidin-1-ylethoxy)nitrobenzene;4-(2-(pyrrolidinyl)ethoxy)-1-nitrobenzene;Pyrrolidine, 1-[2-(4-nitrophenoxy)ethyl]-
• CAS NO: 265654-77-1
• Molecular Formula: C₁₂H₁₆N₂O₃
• Molecular Weight: 236.27
• Product Categories: Amines;blocks;NitroCompounds
• Mol File: 265654-77-1.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 379.3°Cat760mmHg
• Flash Point: 183.2°C
• Appearance: /
• Density: 1.195
• Vapor Pressure: 5.93E-06mmHg at 25°C
• Refractive Index: 1.562
• Storage Temp.: 2-8°C
• PKA: 9.28±0.20(Predicted)
• CAS DataBase Reference: 4-(2-Pyrrolidin-1-ylethoxy)nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-Pyrrolidin-1-ylethoxy)nitrobenzene(265654-77-1)
• EPA Substance Registry System: 4-(2-Pyrrolidin-1-ylethoxy)nitrobenzene(265654-77-1)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 265654-77-1(Hazardous Substances Data)

Usage

General Description

4-(2-Pyrrolidin-1-ylethoxy)nitrobenzene is a chemical compound with the molecular formula C13H16N2O3. It is a nitrobenzene derivative with a pyrrolidine functional group and an ethoxy linker. 4-(2-Pyrrolidin-1-ylethoxy)nitrobenzene is commonly used in organic synthesis and medicinal chemistry, where it serves as a building block for the production of various pharmaceuticals and biologically active molecules. It has been studied for its potential effects on the central nervous system and has shown promise as a potential drug candidate for conditions such as depression and anxiety. Additionally, the nitro group in the compound can serve as a versatile chemical handle for further functionalization and modification, making it a valuable tool in the development of new therapeutic agents.

InChI:InChI=1/C12H16N2O3/c15-14(16)11-3-5-12(6-4-11)17-10-9-13-7-1-2-8-13/h3-6H,1-2,7-10H2

Upstream product

• 7250-67-1 1-(2-chloroethyl)pyrrolidine hydrochloride 
• 824-78-2 4-nitrophenol sodium salt 
• 123-75-1 pyrrolidine 
• 3383-72-0 1-(2-chloroethoxy)-4-nitrobenzene 
• 16365-27-8 2-(4-nitrophenoxy)ethanol 
• 100-02-7 4-nitro-phenol 
• 2955-88-6 1-pyrrolidineethanol 
• 5050-41-9 N-(2-chloroethyl)-pyrrolidine 
• 603-35-0 triphenylphosphine 
• 1972-28-7 diethylazodicarboxylate 
• 28341-54-0 4-(4-nitrophenoxy)butanoic acid 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 50609-01-3 4-(2-pyrrolidinoethoxy)aniline 
• 1142945-81-0 1-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}guanidine trifluoroacetate salt 
• 1430234-72-2 C₂₉H₃₀N₆O₃ 

Relevant articles and documents

Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3

Hybridization strategy is an effective strategy to obtain multi-target inhibitors in drug design. In this study, we assembled the pharmacophores of momelotinib and tandutinib to get a series of 4-piperazinyl-2-aminopyrimidine derivatives. All compounds were tested for the inhibition of JAK2 and FLT3 enzymes, of which, compounds with potent enzyme activities were assayed for antiproliferative activities against three cancer cell lines (HEL, MV4-11, and HL60). The structure-activity relationship studies were conducted through variations in two regions, the “A” phenyl ring and “B” phenyl ring. Compound 14j showed the most balanced in vitro inhibitory activity against JAK2 and FLT3 (JAK2 IC50 = 27 nM, FLT3 IC50 = 30 nM), and it also showed potent inhibition against the above tested cell lines. In the cellular context, 14j strongly induced apoptosis by arresting cell cycle in the G1/S phase, and was selected as a promising JAK2/FLT3 dual inhibitor.

5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER

The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as a drug, notably in the treatment of cancer, as well as pharmaceutical compositions containing such a